Cidara therapeutics to present preclinical data on cd388 at asm microbe 2024 conference

San diego, may 30, 2024 (globe newswire) -- cidara therapeutics, inc. (nasdaq: cdtx), a biotechnology company using its proprietary cloudbreak® platform to develop drug-fc conjugate (dfc) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the american society for microbiology (asm) microbe 2024 conference to be held june 13-17, 2024 at the georgia world congress center in atlanta, georgia.
ASM Ratings Summary
ASM Quant Ranking